pentobarbital will lessen the extent or result of methylprednisolone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use warning/observe.
pentobarbital will decrease the level or result of terbinafine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/check.
pentobarbital will minimize the extent or effect of alosetron by impacting hepatic/intestinal enzyme CYP3A4 metabolism. slight/Significance mysterious.
check carefully (one)pentobarbital will minimize the extent or outcome of tofacitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/observe. Loss of, or diminished response to tofacitinib may arise when coadministered with potent CYP3A4 inducers
pentobarbital will reduce the extent or outcome of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/check. Strong CYP3A4 inducers may possibly reduce suvorexant efficacy; if enhanced suvorexant dose expected, don't exceed twenty mg/working day
pentobarbital will lessen the extent or influence of etonogestrel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/keep track of.
pentobarbital will lower the level or impact of abiraterone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/watch.
buprenorphine subdermal implant and pentobarbital equally maximize sedation. stay clear of or Use Alternate Drug. Limit use to clients for whom choice cure options are insufficient
pentobarbital will decrease the extent or result of tipranavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will decrease the extent or result of triamcinolone acetonide injectable suspension by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use warning/Monitor.
fentanyl iontophoretic transdermal process and pentobarbital each boost sedation. prevent or Use Alternate Drug. Limit use to individuals for whom alternative treatment method options are insufficient
keep track of Closely (2)pentobarbital will minimize the level or outcome of get more info suvorexant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. potent CYP3A4 inducers might minimize suvorexant efficacy; if amplified suvorexant dose required, tend not to exceed 20 mg/working day
pentobarbital will decrease the level or effect of ziprasidone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. insignificant/importance not known.
pentobarbital will lessen the level or outcome of levoketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. slight/Significance mysterious.